Fox Chase Cancer Center News

PHILADELPHIA (August 26, 2019) – Ipafricept will not be studied further for platinum-sensitive ovarian cancer after an early clinical trial revealed increased likelihood for bone toxicity at its most efficacious doses.

PHILADELPHIA (August 26, 2019) - A recent study from a researcher at Fox Chase Cancer Center found that incidence rates of tonsil cancer in the United States are increasing in both high and low socioeconomic groups. This trend has been attributed to increasing chronic oral infections with HPV.

PHILADELPHIA (August 23, 2019) – New data from researchers at Fox Chase Cancer Center shows there may be important genetic differences among different black ethnic subgroups relevant to cancer.

PHILADELPHIA (August 23, 2019) — Evelyn González and Shannon Lynch, MPH, PhD, have received a two-year grant for $125,000 from The Pennsylvania Department of Human Services to provide liver cancer and hepatitis education to at-risk communities in the Philadelphia area. Up to 70 percent of liver cancer cases are caused by modifiable factors, including drug or alcohol use, obesity, diabetes, and infection with hepatitis B or C.

PHILADELPHIA (August 21, 2019) – Fox Chase Cancer Center announces the hiring of Stephanie Greco, MD, who will join the Department of Surgical Oncology on September 3, focusing on melanoma, sarcoma, and GI.

PHILADELPHIA (August 20, 2019) – The immunostimulatory monoclonal antibody elotuzumab, given in combination with lenalidomide and dexamethasone, is approved for the treatment of patients with relapsed or refractory multiple myeloma. The drug binds signaling lymphocytic activation molecule family member 7 (SLAMF7), a protein that is highly expressed on the surface of myeloma cells.

PHILADELPHIA (August 19, 2019) – Fox Chase Cancer Center will proudly participate in the Philadelphia Undy RunWalk to support the Colorectal Cancer Alliance and their mission to end colorectal cancer with national prevention, research, and patient support initiatives. Saturday, September 14, 2019, in Paine’s Park.

PHILADELPHIA (August 16, 2019) – Recently, Fox Chase Cancer Center researchers found a potential way to sensitize a new subset of patients with high-grade serous ovarian carcinoma to PARP inhibitors, a promising drug used in some cases of this disease. Disruption of HSP90 function can lead to death of ovarian cancer cell lines without known defects in DNA repair mechanisms, such as BRCA1/2 mutations, when used in combination with a PARP inhibitor.